Rasna Therapeutics, Inc. Completes Reverse Merger and Becomes a Publicly Traded Company

NEW YORK–(BUSINESS WIRE)– Rasna Therapeutics, Inc., a development stage biotechnology company
focused on the development of cancer drugs, today announced the
successful completion of its merger with the Active With Me, Inc.
(OTC:ATVM). The combined company intends to change its name to Rasna
Therapeutics, Inc. and will trade on the OTC Markets under the symbol
“ATVM.” The Company intends to submit an application to change its
trading symbol.

“Becoming a public company is a key element of our growth strategy, and
the completion of this reverse merger is a significant accomplishment
for Rasna Therapeutics,” said James Tripp, Acting Chief Executive
Officer of Rasna, “We believe that this breakthrough program may have
significant benefits across all forms of leukemia. Our NPM1
program targets the sub-set of acute myeloid leukemia (AML) patients
with the NPM1 mutation and may also benefit the general AML population.
We are aiming to have a lead candidate identified by 2017.”

Rasna Therapeutics is engaged in modulating the molecular targets LSD1
and NPM1, which are implicated in the disease progression of leukemia
and lymphoma. Rasna was formed in 2013 by biotechnology entrepreneur
Gabriele Cerrone, together with distinguished scientists, Dr. Roberto
Pellicciari, a medicinal chemist and the scientific founder of Intercept
Pharmaceuticals, Inc. (ICPT), and Dr. Brunangelo Falini, a physician and
hematologist.

Rasna’s scientific team is comprised of world-renowned experts in blood
cancers such as leukemia and lymphoma. Dr. Riccardo Dalla-Favera is a
board member of Rasna and the director of the Institute for Cancer
Genetics at Columbia University and a member of the National Academy of
Sciences, Dr. Falini is the Director of the Hematology Institute at the
University of Perugia, Italy and Dr. Pier Giuseppe Pelicci, a
collaborator with Rasna, is the Chairman of the Department of
Experimental Oncology at the European Institute of Oncology.

About Rasna Therapeutics, Inc.

Rasna Therapeutics, Inc. is a development stage biotechnology company
focused primarily on the development of drug candidates for leukemia and
lymphoma. Abnormal epigenetic modification is recognized to play an
important role in the pathogenesis of acute myeloid leukemia (AML),
leading to silencing of genes involved in tumor suppression and cellular
reproduction. Rasna’s focus on inhibition of lysine specific
demethylase-1 (LSD1), an enzyme involved in epigenetic control,
represents a promising and novel approach towards AML. Rasna has
developed novel irreversible and reversible LSD1 regulators that have
shown appropriate effects on the LSD1 gene in-vitro and in
IND-enabling pre-clinical studies.

Rasna Therapeutics Forward-Looking Statements

This press release contains “forward-looking statements” as that term is
defined in the Private Securities Litigation Reform Act of 1995,
regarding the research, development and commercialization of
pharmaceutical products. Such forward-looking statements are based on
current expectations and involve inherent risks and uncertainties,
including factors that could delay, divert or change any of them, and
could cause actual outcomes and results to differ materially from
current expectations. No forward-looking statement can be guaranteed.
Forward-looking statements in the press release should be evaluated
together with the many uncertainties that affect Rasna Therapeutics’
business and Rasna Therapeutics undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new
information, future events, or otherwise.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160817005347/en/